Lisanti Capital Growth LLC Acquires Shares of 4,005 Penumbra, Inc. (NYSE:PEN)

Lisanti Capital Growth LLC acquired a new stake in Penumbra, Inc. (NYSE:PEN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 4,005 shares of the company's stock, valued at approximately $1,071,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its stake in shares of Penumbra by 0.6% during the 4th quarter. Bank of New York Mellon Corp now owns 294,620 shares of the company's stock worth $69,966,000 after purchasing an additional 1,823 shares during the period. Proficio Capital Partners LLC purchased a new stake in Penumbra during the fourth quarter worth $3,553,000. QRG Capital Management Inc. grew its position in shares of Penumbra by 4.8% during the 4th quarter. QRG Capital Management Inc. now owns 1,584 shares of the company's stock valued at $376,000 after acquiring an additional 72 shares during the period. Norden Group LLC raised its stake in shares of Penumbra by 2.6% during the 4th quarter. Norden Group LLC now owns 5,338 shares of the company's stock worth $1,268,000 after buying an additional 135 shares during the period. Finally, Jones Financial Companies Lllp increased its stake in Penumbra by 25.0% during the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock worth $89,000 after buying an additional 75 shares in the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Stock Down 0.5%

Shares of PEN traded down $1.15 during midday trading on Wednesday, hitting $249.53. The company had a trading volume of 396,058 shares, compared to its average volume of 451,589. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00. The firm has a market capitalization of $9.66 billion, a P/E ratio of 235.41, a P/E/G ratio of 2.29 and a beta of 0.47. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.68 and a current ratio of 6.30. The company's 50-day simple moving average is $271.67 and its 200-day simple moving average is $268.14.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. The company had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. Penumbra had a return on equity of 11.14% and a net margin of 3.41%. Penumbra's revenue for the quarter was up 16.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.41 EPS. As a group, sell-side analysts expect that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Activity

In other Penumbra news, Director Bridget O'rourke sold 100 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $286.15, for a total transaction of $28,615.00. Following the sale, the director owned 5,423 shares of the company's stock, valued at approximately $1,551,791.45. This trade represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arani Bose sold 12,000 shares of the company's stock in a transaction on Friday, April 25th. The shares were sold at an average price of $298.73, for a total transaction of $3,584,760.00. Following the completion of the transaction, the director owned 302,819 shares of the company's stock, valued at approximately $90,461,119.87. The trade was a 3.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 114,210 shares of company stock valued at $31,582,595 over the last 90 days. Insiders own 5.00% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on PEN shares. UBS Group restated a "buy" rating and set a $330.00 price target (up from $320.00) on shares of Penumbra in a research report on Thursday, April 24th. Royal Bank Of Canada increased their price target on shares of Penumbra from $315.00 to $330.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Wells Fargo & Company lifted their price target on shares of Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. Stifel Nicolaus set a $318.00 price objective on Penumbra and gave the company a "buy" rating in a report on Thursday, April 24th. Finally, BTIG Research reissued a "buy" rating on shares of Penumbra in a research note on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Penumbra has a consensus rating of "Moderate Buy" and a consensus target price of $302.40.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.